MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

In early, levodopa-naive PD patients, Stalevo induced more dyskinesia than similar dosages of levodopa/carbidopa, so the regimen tested (target maintenance dose Stalevo 100 four-times daily given ...

Vistagen , a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced ...

ion.ucl.ac.uk OBJECTIVES New treatments are now becoming available for the management of levodopa induced dyskinesias in Parkinsons's disease. However, assessment of their efficacy is limited by the ...

Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...